Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Receivables (2022 - 2025)

Historic Receivables for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $215.8 million.

  • Axsome Therapeutics' Receivables rose 5596.52% to $215.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.8 million, marking a year-over-year increase of 5596.52%. This contributed to the annual value of $155.5 million for FY2024, which is 4489.84% up from last year.
  • Latest data reveals that Axsome Therapeutics reported Receivables of $215.8 million as of Q3 2025, which was up 5596.52% from $218.6 million recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' Receivables peaked at $218.6 million during Q2 2025, and registered a low of $16.2 million during Q2 2022.
  • Moreover, its 4-year median value for Receivables was $111.2 million (2023), whereas its average is $112.4 million.
  • As far as peak fluctuations go, Axsome Therapeutics' Receivables soared by 41375.17% in 2023, and later skyrocketed by 4489.84% in 2024.
  • Axsome Therapeutics' Receivables (Quarter) stood at $46.8 million in 2022, then soared by 129.34% to $107.3 million in 2023, then surged by 44.9% to $155.5 million in 2024, then soared by 38.8% to $215.8 million in 2025.
  • Its last three reported values are $215.8 million in Q3 2025, $218.6 million for Q2 2025, and $176.2 million during Q1 2025.